A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
The purpose of this study is to assess the efficacy of the amivantamab and lazertinib combination, compared with osimertinib, in participants with epidermal growth factor receptor (EGFR) mutation (Exon 19 deletions [Exon 19del] or Exon 21 L858R substitution) positive, locally advanced or metastatic non-small cell lung cancer (NSCLC).
Inclusion Criteria:
Exclusion Criteria:
Porto Alegre, 90610-000, Brazil
São Paulo, 01246 000, Brazil
Wuhan, 430030, China
Sain-Herblain, 44800, France
Farkasgyepü, 8582, Hungary
Osaka Sayama Shi, 589 8511, Japan
Toon-shi, 791-0295, Japan
Toyonaka-shi, 560-8552, Japan
Warsaw, 02-781, Poland
Kuzmolovsky, 188663, Russia
Adana, 01250, Turkey (Türkiye)
Istanbul, 34098, Turkey (Türkiye)
Istanbul, 34722, Turkey (Türkiye)
Dnipro, 49102, Ukraine